Your Knee Called. It Wants New Cartilage.
Renovare Therapeutics launches from stealth with up to $33.5M in ARPA-H funding for osteoarthritis regeneration.
Jeff Martin
No Drugs. Just Ultrasound.
SonoNeu exits stealth with $5.2M from a $41.3M ARPA-H program to bring sonogenetics to the clinic.
Ternary Therapeutics
AI-driven platform designing molecular glue therapeutics for undruggable targets in immunology and neuroinflammation.
Can You Make Ketamine…Boring?
Alar Pharmaceuticals reports positive Phase 1 results for long-acting injectable ketamine ALA-3000 in treatment-resistant depression.
Affinia Continues To Accumulate Wins
Affinia Therapeutics gets Health Canada nod for UPBEAT gene therapy trial in BAG3 cardiomyopathy.
The Denali Diaspora Hits the Clinic
Tenvie Therapeutics doses first patient in Phase 1 trial of CNS-penetrant NLRP3 inhibitor TNV262.
The Antibody-Drug Conjugate Landscape
HOUSTON tracks 229 companies across the ADC ecosystem — 187 therapeutic developers, 18 platform companies, and 15 CDMOs/services. In just four months, the space generated $2.73B+ in licensing deals.
Stipple Bio
Epitope-resolution platform discovering tumor-specific cell surface targets for precision ADCs and next-generation oncology therapeutics.
A Hundred Million Reasons to Pay Attention
Stipple Bio emerges from stealth with an oversubscribed $100M Series A to advance its precision oncology ADC platform.
Early-Stage AI In Biotech
The most comprehensive mapping of early-stage AI in biotech — 569 companies spanning drug discovery, diagnostics, digital health, and the tools infrastructure powering all of it. Featuring $8B+ in deal value tracked since December 2025.